At a recent conference, a forensic toxicologist mentions something you have been hearing more about: a veterinary sedative called medetomidine is showing up in the fentanyl supply in several East Coast cities. It is replacing xylazine in some markets. Your laboratory has not seen it yet, but the question is already forming: should you be preparing for it, and if so, how far ahead should you be thinking?
The answer depends on your region, your testing population, and how closely the pattern follows the trajectory that laboratories saw with xylazine. But if the xylazine experience taught laboratories anything, it is that the gap between “first detected somewhere” and “showing up in our casework” can close faster than expected.
At UTAK, we have spent more than 50 years working alongside laboratories navigating exactly these kinds of shifts. We supported laboratories through the xylazine adoption cycle, from early surveillance conversations through QC development and method validation, and the pattern we are seeing with medetomidine feels familiar. The laboratories that came through xylazine most smoothly were the ones that started monitoring and planning before demand hit. That experience shapes how we are thinking about medetomidine: not as an immediate crisis for every laboratory, but as a compound worth watching closely and preparing for methodically.
What Is Medetomidine?
Medetomidine is an alpha-2 adrenergic receptor agonist approved by the FDA exclusively for veterinary use, primarily for canine sedation and analgesia [1]. It is a racemic mixture of two enantiomers: dexmedetomidine, which is pharmacologically active and also used as an intravenous sedative in human critical care settings, and levomedetomidine, which has minimal pharmacological activity [2]. In veterinary practice, medetomidine produces deep sedation, analgesia, and muscle relaxation.
As an adulterant in the illicit drug supply, medetomidine functions similarly to xylazine: it deepens and extends the sedative effect of fentanyl, making the product feel more potent to the end user. However, medetomidine is considerably more potent than xylazine at the alpha-2 receptor, with published estimates ranging from 100 to 200 times greater potency depending on the model and receptor subtype [3,4]. This potency difference has clinical consequences. Published case series from Philadelphia, Chicago, and Pittsburgh describe overdose presentations characterized by profound bradycardia, hypotension, and prolonged sedation with limited or no response to naloxone [5,6,7]. A severe withdrawal syndrome, distinct from opioid and xylazine withdrawal, has also emerged, characterized by autonomic hyperactivity including dangerous hypertension, tachycardia, and agitation that often requires ICU-level management with dexmedetomidine infusion [5,6,7].
Medetomidine is not currently scheduled as a controlled substance at the federal level, though some states are pursuing scheduling legislation. Pennsylvania, for example, has introduced legislation to classify medetomidine as a Schedule III controlled substance, following the model used for xylazine under Act 17 of 2024 [8]. Its status as an uncontrolled veterinary drug, available through veterinary supply channels, contributes to its accessibility in illicit manufacturing.
What the Surveillance Data Shows
Medetomidine was first identified in illicit drug samples in Maryland in 2022, with DEA NFLIS submissions beginning as early as 2021 [1,9]. For the first two years, detections were relatively sparse. That changed in 2024. A national mail-based drug checking program analyzing over 11,000 samples between December 2022 and April 2025 identified medetomidine in approximately 2.4% of all samples, with pronounced growth beginning in June 2024 [10]. When detected, medetomidine commonly co-occurred with fentanyl and xylazine.
The concentration of cases in specific markets has been striking. In Philadelphia, medetomidine was detected in 72% of illegal opioid samples tested during the last four months of 2024, rapidly displacing xylazine, which dropped from 98% to 31% of samples during the same period [5]. In May 2024, a mass overdose event in Chicago resulted in nearly 180 patients treated across three emergency departments over a single week, the largest confirmed medetomidine-involved overdose cluster reported to date [6]. In Pittsburgh, a case series documented 23 patients hospitalized with severe withdrawal between October 2024 and March 2025 [7].
The geographic trajectory echoes xylazine’s spread. Initial concentration in the Northeast and Mid-Atlantic has been followed by detections in the Midwest, with reports emerging from California, Tennessee, and New York [1,11,12]. Multiple state health departments have issued public health alerts, and the American Society of Addiction Medicine released an emerging challenge alert in early 2026 [3]. The data suggest medetomidine is not yet everywhere, but its trajectory in the markets where it has appeared has been steep, and the pattern is familiar. Laboratories that monitored xylazine early gained months of preparation time. The same opportunity exists now.
Why Medetomidine Is a Detection Challenge
From an analytical perspective, medetomidine presents several challenges that laboratories should understand before it arrives in their casework.
No commercial immunoassays are available for clinical use. Existing xylazine immunoassays do not cross-react with medetomidine [14]. Lateral flow immunoassay test strips have been developed for harm reduction drug checking applications, but these are not cleared for clinical diagnostic use and have shown variable sensitivity depending on the enantiomeric composition of the sample [15]. For the foreseeable future, laboratory detection of medetomidine in biological specimens requires mass spectrometry.
LC-MS/MS is the primary detection pathway. Published methods have demonstrated detection of medetomidine in blood with limits as low as 0.1 ng/mL using liquid-liquid extraction [2]. A validated LC-MS/MS assay for urine detection has been described using minimal sample preparation, a 60-minute hydrolysis incubation, and a 7-minute chromatographic run time [16]. These methods are accessible to laboratories with existing mass spectrometry capabilities, but they require intentional panel expansion.
Metabolite targeting is essential for urine specimens. This is perhaps the most important analytical consideration. Parent medetomidine may not be detected in urine even with comprehensive drug screening. Research from Philadelphia found that 3-hydroxy-medetomidine, detected after enzymatic glucuronidase pre-treatment, was the most reliable urinary marker of exposure [17]. In a Pittsburgh case series, only 2 of 10 patients with confirmed medetomidine exposure had detectable parent compound on comprehensive urine drug screening using LC-QTOF-MS, while all 10 were positive when metabolite testing with glucuronidase pre-treatment was applied [7]. For laboratories considering urine-based detection, incorporating 3-hydroxy-medetomidine as a target analyte and including a hydrolysis step in sample preparation is likely to be the difference between detection and a false negative.
Circulating concentrations are low. Published case series report medetomidine blood concentrations ranging from 0.1 to 32 ng/mL in fatal overdoses and 0.1 to 16 ng/mL in non-fatal cases [2]. These concentrations demand sensitive analytical methods, and laboratories should consider whether their current instrumentation and sample preparation workflows can achieve the required limits of detection.
Enantiomeric analysis may have forensic value. All illicit medetomidine samples analyzed to date have been racemic, containing both dexmedetomidine and levomedetomidine, which distinguishes them from pharmaceutical dexmedetomidine [18]. Chiral LC-MS/MS methods have been described but are not necessary for routine clinical or forensic detection of exposure. They may, however, have applications in distinguishing illicit medetomidine from diverted pharmaceutical dexmedetomidine in forensic casework.
Lessons from Xylazine: A Framework for Preparedness
In our work with forensic and clinical laboratories over the past several years, we have seen how the xylazine timeline unfolded in practice. When xylazine first appeared in the drug supply, most laboratories did not have dedicated testing in place. By the time demand for testing became widespread, laboratories that had begun monitoring early and laying the groundwork for method development were months ahead of those that waited for casework to force the issue.
The xylazine case study illustrates how laboratories have successfully implemented testing for a novel compound when commercial options were limited. Several principles from that experience translate directly to medetomidine preparedness:
Monitor regional surveillance data regularly. Track NFLIS reports, state health department alerts, CFSRE NPS Discovery data, and drug checking program findings for your geographic area. Medetomidine’s distribution remains regionally concentrated, so local and state-level intelligence is more actionable than national trends alone.
Evaluate your current panel coverage. Determine whether your existing LC-MS/MS panels could detect medetomidine and its primary urinary metabolite, 3-hydroxy-medetomidine, or whether method expansion would be needed. If medetomidine is not currently in your analyte library, consider whether your instrumentation and extraction workflow could accommodate it without a full revalidation.
Review your sample preparation workflow. Given the importance of 3-hydroxy-medetomidine for reliable urine detection, evaluate whether enzymatic glucuronidase hydrolysis is part of your current sample preparation. Laboratories that already include a hydrolysis step for other analytes may find that adding medetomidine metabolites to their panel is a relatively straightforward expansion.
Assess QC readiness early. If your laboratory were to add medetomidine to a testing panel, are appropriate QC materials available or sourced? A practical approach includes a low QC near the lower limit of quantification to monitor sensitivity, a mid-range QC for precision assessment, and a high QC to evaluate linearity. Waiting until the method is built to think about QC adds unnecessary delays. In our experience, laboratories that plan QC sourcing alongside method development rather than after it move from validation to reporting significantly faster.
Document your monitoring and response plan. Even before you add testing, having a documented surveillance and response framework strengthens your laboratory’s audit defensibility and ensures that the decision to implement testing is driven by defined triggers rather than reactive pressure. This might include a quarterly review of surveillance data, a threshold for casework encounters that would initiate method development, and an identified pathway for QC sourcing and validation.
Frequently Asked Questions
Is medetomidine detected by standard opioid or benzodiazepine immunoassays?
No. Medetomidine is not an opioid and does not cross-react with standard immunoassay panels, including those designed for xylazine. Dedicated testing using mass spectrometry-based methods is required for laboratory confirmation of exposure.
How does medetomidine differ from xylazine pharmacologically?
Both are alpha-2 adrenergic agonists used in veterinary medicine, but medetomidine is significantly more potent at the receptor level. It also produces a distinct and severe withdrawal syndrome, characterized by autonomic hyperactivity including dangerous hypertension and tachycardia, that has required ICU-level management in published case series. Unlike xylazine, medetomidine has not yet been associated with the necrotic skin wounds that became a hallmark of chronic xylazine exposure.
Is medetomidine a controlled substance?
Not at the federal level as of this writing. Some states, including Pennsylvania, have pursued or are pursuing state-level scheduling. Its status as an uncontrolled veterinary drug available through legitimate supply channels contributes to its accessibility in illicit drug manufacturing.
Should my laboratory add medetomidine testing now?
That depends on your region, your testing population, and what your surveillance data is telling you. Laboratories in areas where medetomidine has been detected in the drug supply, particularly in the Northeast and Midwest, may want to prioritize method development. Laboratories in areas where medetomidine has not yet been identified may be well served by a monitoring posture with a defined trigger for implementation. The real question is whether you have a plan in place so that the decision to add testing is proactive rather than reactive.
What specimen type is best for medetomidine detection?
Blood and urine are both viable, but urine detection benefits significantly from targeting the 3-hydroxy-medetomidine metabolite after enzymatic hydrolysis, as parent medetomidine may not be present in detectable concentrations in urine. For forensic postmortem casework, blood remains the standard matrix. In either case, laboratories should ensure their methods achieve sufficient sensitivity given the low concentrations reported in published case series.
How UTAK Can Help
We have been through this cycle before with xylazine, and the laboratories that came through it most smoothly were the ones that started the conversation early. Medetomidine may not be in your casework today, but the surveillance signals suggest that for many laboratories it is a matter of when, not if. The time to think about QC sourcing, panel design, and method validation strategy is before the first positive result demands it.
Our technical team has worked through these challenges across hundreds of laboratory implementations over 50 years. If medetomidine is on your radar, or if you are trying to figure out whether it should be, we are here to talk it through. Sometimes a conversation with people who have seen these problems across many different laboratory contexts can shortcut weeks of planning.
Reach out at welovecontrol@utak.com or call 888.882.5522.
References
[1] Lynch MJ, Pizon AF, Yealy DM. Emergence of medetomidine in the illicit drug supply: implications for emergency care and withdrawal management. Annals of Emergency Medicine. 2026. https://doi.org/10.1016/j.annemergmed.2025.12.004
[2] Walton SE, Stang BN, Kacinko S, Papsun DM, Logan BK, Krotulski AJ. Medetomidine quantitation and enantiomer differentiation in biological specimens collected after fatal and non-fatal opioid overdoses. Journal of Analytical Toxicology. 2025;49(8):551–558. https://pubmed.ncbi.nlm.nih.gov/40338638/
[3] American Society of Addiction Medicine. Emerging challenge alert: medetomidine in the illicit drug supply. 2026.
[4] Sood N. Rise of illicit medetomidine use: a worrisome trend. American Journal on Addictions. 2025;34(5):558–561. https://doi.org/10.1111/ajad.70030
[5] Huo S, London K, Murphy L, et al. Notes from the field: suspected medetomidine withdrawal syndrome among fentanyl-exposed patients — Philadelphia, Pennsylvania, September 2024–January 2025. MMWR Morb Mortal Wkly Rep. 2025;74(15):266–268. https://doi.org/10.15585/mmwr.mm7415a2
[6] Nham A, Le JN, Thomas SA, et al. Overdoses involving medetomidine mixed with opioids — Chicago, Illinois, May 2024. MMWR Morb Mortal Wkly Rep. 2025;74(15):258–265. https://doi.org/10.15585/mmwr.mm7415a1
[7] Ostrowski SJ, Tamama K, Trautman WJ, et al. Notes from the field: severe medetomidine withdrawal syndrome in patients using illegally manufactured opioids — Pittsburgh, Pennsylvania, October 2024–March 2025. MMWR Morb Mortal Wkly Rep. 2025;74(15):269–271. https://doi.org/10.15585/mmwr.mm7415a3
[8] Pennsylvania State Senate. Co-sponsorship memorandum: scheduling medetomidine as a Schedule III controlled substance. 2025. https://www.palegis.us/senate/co-sponsorship/memo?memoID=46801
[9] U.S. Drug Enforcement Administration. Medetomidine and dexmedetomidine submissions: NFLIS street report. October 2024. https://www.dea.gov/sites/default/files/2025-01/NIIP-001-25%20Street%20Report%20-%20Oct%202024.pdf
[10] Sibley AL, Bedard ML, Tobias S, et al. Emergence of medetomidine in the unregulated drug supply and its association with hallucinogenic effects. Drug and Alcohol Review. 2025;44(7):1896–1906. https://doi.org/10.1111/dar.70024
[11] New York State Department of Health. Public health alert: medetomidine detected in the unregulated drug supply. December 19, 2025. https://www.health.ny.gov/press/releases/2025/2025-12-19_synthetic_sedative.htm
[12] Tennessee Bureau of Investigation, Tennessee Department of Health. Public safety alert: medetomidine detected in Tennessee illicit drug supply. September 2025.
[13] American Veterinary Medical Association. Health officials finding different illicit veterinary sedative in US drug supply. JAVMA. June 2025. https://www.avma.org/news/health-officials-finding-different-illicit-veterinary-sedative-us-drug-supply
[14] Recent advances in the identification and quantification of xylazine and medetomidine in biological specimens. Forensic Toxicology Bulletin. 2025. https://www.tandfonline.com/doi/full/10.1080/17576180.2025.2572959
[15] Amate A, Lieberman M. Chiral sensitivity of medetomidine lateral flow immunoassay test strips. Harm Reduction Journal. 2026;23:19. https://doi.org/10.1186/s12954-025-01387-6
[16] Kodger J, Cassella-McLane G, Iozzo M, El-Khoury JM. Liquid chromatography-mass spectrometry quantitation and prevalence of medetomidine and xylazine in New Haven, Connecticut. Clinica Chimica Acta. 2026;581:120741. https://pubmed.ncbi.nlm.nih.gov/41314587/
[17] Murphy L, Krotulski A, Hart B, et al. Clinical characteristics of patients exposed to medetomidine in the illicit opioid drug supply in Philadelphia — a case series. Clinical Toxicology. 2025;63:438–441.
[18] Sisco E, Ventura M, Shuda S. Enantiomeric determination of medetomidine in street drug samples (August 2024–February 2025) and implications for immunoassay test strip analysis. Drug Testing and Analysis. 2025;17(12):2347–2353. https://doi.org/10.1002/dta.3947
